scout

Authors

Kirsten M. Leu, MD
Latest Article

Chemotherapy for Resectable and Advanced Pancreatic Cancer

This article will review the pertinent data on the use of chemotherapy for all stages of pancreatic cancer. For patients with metastatic disease, fluorouracil (5-FU) was the standard of care for several decades until a single

Kirsten Pyle, MBA, JD
Latest Article

Are Cancer Patients Subject to Employment Discrimination?

We sought to determine whether patients undergoing treatment for cancer had experienced discrimination in employment and, if so, how that discrimination was manifested. We also sought to determine what variables affected the rate of discrimination, including age, gender, occupation, and employer size.

Klaus Diergarten, MD
Latest Article

Infusional 5-FU, Folinic Acid, Paclitaxel, and Cisplatin for Metastatic

Our phase II study results demonstrating high efficacy and low toxicity for a weekly schedule of high-dose, 24-hour infusional 5-fluorouracil(5-FU)/folinic acid (HD5-FU/FA) in intensively pretreated patients with metastatic

Kohkan Shamsi, MD, PhD
Latest Article

Eovist Injection and Resovist Injection: Two New Liver-Specific Contrast Agents for MRI

In this short review, we describe two new liver-specific contrast agents for MRI that are in clinical development. The main differences among the liver-specific contrast agents available at present are also discussed briefly.

Koichi Hirata, MD
Latest Article

UFT and Mitomycin Plus Tamoxifen for Stage II, ER-Positive Breast Cancer

A trial was designed to examine the combination of UFT and mitomycin (Mutamycin) plus tamoxifen (Nolvadex) as postoperative adjuvant therapy in the treatment of patients with stage II, estrogen receptor (ER)-positive

Konstanty Wierzba, PhD
Latest Article

UFT and Its Metabolites Inhibit Cancer-Induced Angiogenesis via a VEGF - Related Pathway

Treatment with UFT for spontaneous lung metastasis of murine renal carcinoma (RENCA) after resection of the primary tumor has resulted in significant prolongation of the life span of tumor-bearing animals. UFT inhibited the growth of metastatic nodules in the lung, apparently via decreased density of microvessels in the metastatic foci. Subsequent experiments used dorsal air sac assay to directly trace newly forming microvessels.

Kornelia Polyak, MD, PhD
Latest Article

Tumor Heterogeneity: The Lernaean Hydra of Oncology?

Intratumor heterogeneity is one of the biggest challenges in cancer diagnosis and treatment. Despite morphologic and clinical recognition of tumor heterogeneity, an understanding of it at a molecular level has only begun to emerge in recent years.

Kozo Yoshimori, MD
Latest Article

UFT Plus Cisplatin in Advanced Non-Small-Cell Lung Cancer: Interim Analysis of 67 Patients

A single-institution phase II study indicated that combination chemotherapy using UFT (tegafur and uracil) plus cisplatin (Platinol) in patients with non-small-cell lung cancer was active with less host toxicity than other cisplatin-

Krishna Gundabolu, MBBS
Latest Article

The Different Faces of Disseminated Intravascular Coagulation in Solid Tumors: How to Identify and Manage

“Treat the underlying cause” has been the classic mantra for the treatment of disseminated intravascular coagulation. Whenever feasible in disseminated intravascular coagulation associated with solid tumors, this principle appears to hold good.

Krishna Patel, MD
Latest Article

Neoadjuvant Treatment for Surgically Resectable Metastatic Colorectal Cancer: Is There an Optimal Succession?

It remains difficult to decipher which patients are appropriate candidates for conversion therapy vs upfront surgery. Therefore, in predicting potential outcomes, several factors should be considered. Here, we will attempt to address such factors and provide insights.

Krishnansu S. Tewari, MD
Latest Article

Anti-Angiogenesis Therapy in Gynecologic Malignancies

The purpose of this paper is to provide a review of site-specific treatment options that involve the targeting of angiogenesis in gynecologic malignancies.

Krista Treichel, RN
Latest Article

The Absent-Minded Professor: An Unusual Complication of Melanoma

The University of Colorado Health Sciences Center holds weekly second opinion conferences focusing on cancer cases that represent most major cancer sites. Patients seen for second opinions are evaluated by an oncologist.

Kristen A. Marrone, MD
Latest Article

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.

Kristen Fessele, RN, MSN
Latest Article

Targeting Angiogenesis in Solid Tumors

A growing number of novel antiangiogenic agents are entering clinical trials to study their clinical safety and efficacy. A few, such as bevacizumab (Avastin), sorafenib (Nexavar), and sunitinib (Sutent), have received US Food and Drug Administration approval and are already in widespread clinical use. As knowledge about the intricacies of intracellular signaling within multiple tumor types expands, agents with the capacity to impact these pathways are being incorporated into additional clinical trials alone and in combination with other targeted and/or traditional antineoplastic agents. Early clinical trials have focused on highly vascular tumor types, as well as those known to significantly overexpress the VEGF (vascular endothelial growth factor) receptor family. This article aims to review the status of antiangiogenic therapy in selected tumor types and discuss areas for further research.

Kristen M. Livesey, MD
Latest Article

Breast Cancer: Never Too Young for a Functional Assessment?

Geriatricians would argue that biological age alone should not be used to estimate a patient's anticipated tolerance for cancer therapy.

Kristen Mckinney, MD
Latest Article

A Man With Changes in the Urinary Bladder: Benign Metaplasia or Adenocarcinoma?

The patient is a 39-year-old man who presents with pelvic lymphadenopathy. He has a history of ureteral reflux disease, recurrent nephrolithiasis, right nephrectomy, ileal loop diversion of the left ureter, and radical cystectomy for “bladder cancer,” which he underwent 3 years ago. The lymphadenopathy was discovered incidentally during recent imaging.

Kristin Bradley, MD
Latest Article

Current Controversies in the Management of Hodgkin's Lymphoma

Despite significant improvements in the treatment of Hodgkin's lymphoma over the past 2 decades, physicians continue to face dilemmas in therapy for the disease, and many cured patients live with complications of treatment. Newer therapeutic options are still needed for the disease, to minimize complications and to improve the treatment of patients in relapse. This review considers the treatment of Hodgkin's lymphoma in younger patients, addressing such issues as which patients with early-stage disease may require radiotherapy, what prognostic factors provide information that can affect treatment choices in patients with advanced disease, and what we have learned about treatment complications in this setting.

Kristin K. Zorn, MD
Latest Article

PARP Inhibition in Epithelial Ovarian Cancer: High Hopes Undergo a Reality Check

This article reviews the trials that have been conducted with PARP inhibitors in epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer, and places the impact of those results in the larger context of PARP inhibitor development.

Kristin Knight, MS
Latest Article

Hearing Loss in Pediatric Cancer Survivors Treated With Cisplatin

Cisplatin is effective in treating several types of childhood cancers (eg, CNS tumors, osteosarcoma, hepatoblastoma, neuroblastoma, germ cell tumors). It is the most ototoxic drug used clinically, and hearing loss is a well-recognized toxicity of cisplatin therapy.

Kristin M. Leiferman, MD
Latest Article

Anaphylaxis: Implications of Monoclonal Antibody Use in Oncology

The phenomenon of anaphylaxis was discovered by Portier and Richet in 1903.[1,2] They injected dogs with toxins from sea anemone with the intent of generating protective antibodies. Unexpectedly, they found that certain dogs became ill with a rapid heartbeat and collapse. Because this syndrome was the precise opposite of protection or prophylaxis, they termed it anaphylaxis.

Kristina Gerszten, MD
Latest Article

Cancer of the Cervix: Current Management and New Approaches: Review 2

This article summarizes the current management of patients with newly diagnosed cervical cancer. The topics range from the management of early-stage disease to the phase III randomized studies that have established the current standard of care for patients with locally advanced cancer of the cervix. New approaches to combined-modality therapy with the goal of improving outcomes and decreasing complications are also described.

Kristina Goutsouliak, MD
Latest Article

Management Considerations in Cancer Patients With Rheumatoid Arthritis

Patients with cancer and concomitant rheumatoid arthritis pose special challenges. Many therapies for rheumatoid arthritis can increase the risk of adverse events during cancer therapy because they are immunosuppressive.

Kristina Karasek, MD
Latest Article

Changing Concepts in the Management of Endometrial Cancer

Endometrial carcinoma was a clinically staged disease until the late 1980s, at which point, staging changed to a surgicopathologically defined system. This change in staging, in turn, altered the clinical management of this

Kristina L. M. Novick, MD
Latest Article

ACR Appropriateness Criteria® Ductal Carcinoma in Situ

Management of ductal carcinoma in situ (DCIS) commonly involves excision, radiotherapy, and hormonal therapy. Radiotherapy is employed for local control in breast conservation. Evidence is evolving for several radiotherapy techniques exist beyond standard whole-breast irradiation.

Kristopher Dennis, MD, FRCPC
Latest Article

Palliative RT Research in Prostate Cancer: Understanding the Past, Anticipating the Future

Moving forward, perhaps no recent development in the use of RT in metastatic prostate cancer has captured greater attention than the use of radium-223 in metastatic castration-resistant prostate cancer (mCRPC).

Krystyna Frenkel, PhD
Latest Article

Commentary (Frenkel): Chronic Inflammation and Cancer

The review by Drs. Shacter and Weitzman is an excellent and timely contribution to the field of carcinogenesis. The issue of chronic inflammation as a progenitor of cancer development has been a controversial one. To prove the importance of chronic inflammation (and the factors released in the process) to carcinogenesis, the authors provide a thorough and logical presentation of the experimental results described in the literature, including their own work. This compilation of the existing data should dispel any doubts about the association of chronic inflammation to cancer. I will review the main points discussed by the authors.

Krystyna Kiel, MD
Latest Article

Book Review: The Alternative Medicine Handbook: The Complete Reference Guide to Alternative and Complementary Therapies

Many oncologists are barraged with questions and declarations from patients regarding therapies and products that

Krzysztof Misiukiewicz, MD
Latest Article

Time to Change the Treatment Paradigms in Anaplastic Thyroid Carcinoma

In rare diseases, the “magic” lies in close collaboration between individual investigators at academic institutions, the pharmaceutical industry, and funding institutions such as the National Cancer Institute.

Krzysztof Mrózek, MD, PhD
Latest Article

Acute Myeloid Leukemia With Adverse Cytogenetic Risk

Acute myeloid leukemia (AML) encompasses multiple disease entities that differ with regard to marrow morphology, cytochemistry, immunophenotype, pretreatment clinical characteristics, and treatment outcome.

Kun He, PhD
Latest Article

Liposomal Doxorubicin in Combination With Bortezomib for Relapsed or Refractory Multiple Myeloma

Liposomal doxorubicin received FDA approval for use in combination with bortezomib in patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.